Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (71-80 of 198) with videos related to

Pageof 20
Sort By:
Diagnostics (Basel, Switzerland)|August 26, 2022
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical DiagnosticsCristin Roma, Alessandra Sacco, Laura Forgione, et al.
Critical Reviews in Oncology/Hematology|August 31, 2015
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumorsPasqualina Giordano, Anna Manzo, Agnese Montanino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
Expert Review of Anticancer Therapy|November 22, 2018
The role of circulating free DNA in the management of NSCLCRiziero Esposito Abate, Raffaella Pasquale, Francesca Fenizia, et al.
Future Oncology (London, England)|August 3, 2019
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Oncology Reports|July 6, 2006
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancerAlessandro Morabito, Raffaele Longo, Domenico Gattuso, et al.
International Journal of Environmental Research and Public Health|December 24, 2021
A Delphi Consensus Approach for the Management of Chronic Pain during and after the COVID-19 EraMarco Cascella, Luca Miceli, Francesco Cutugno, et al.
Biomed Research International|December 24, 2013
Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technologyCristin Roma, Claudia Esposito, Anna Maria Rachiglio, et al.
Expert Review of Anticancer Therapy|February 10, 2012
Cetuximab in non-small-cell lung cancerGuido Carillio, Agnese Montanino, Raffaele Costanzo, et al.
Journal of Translational Medicine|January 25, 2020
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapyAngela Mauriello, Carmen Manolio, Beatrice Cavalluzzo, et al.
Pageof 20

Showing results (71-80 of 198) with videos related to

Sort By:
Pageof 20
Diagnostics (Basel, Switzerland)|August 26, 2022
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical DiagnosticsCristin Roma, Alessandra Sacco, Laura Forgione, et al.
Critical Reviews in Oncology/Hematology|August 31, 2015
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumorsPasqualina Giordano, Anna Manzo, Agnese Montanino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancerMassimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
Expert Review of Anticancer Therapy|November 22, 2018
The role of circulating free DNA in the management of NSCLCRiziero Esposito Abate, Raffaella Pasquale, Francesca Fenizia, et al.
Future Oncology (London, England)|August 3, 2019
Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.
Oncology Reports|July 6, 2006
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancerAlessandro Morabito, Raffaele Longo, Domenico Gattuso, et al.
International Journal of Environmental Research and Public Health|December 24, 2021
A Delphi Consensus Approach for the Management of Chronic Pain during and after the COVID-19 EraMarco Cascella, Luca Miceli, Francesco Cutugno, et al.
Biomed Research International|December 24, 2013
Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technologyCristin Roma, Claudia Esposito, Anna Maria Rachiglio, et al.
Expert Review of Anticancer Therapy|February 10, 2012
Cetuximab in non-small-cell lung cancerGuido Carillio, Agnese Montanino, Raffaele Costanzo, et al.
Journal of Translational Medicine|January 25, 2020
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapyAngela Mauriello, Carmen Manolio, Beatrice Cavalluzzo, et al.
Pageof 20